Pediatric juvenile idiopathic arthritis is a disease of discordance between symptom control and structural protection. A child with oligoarticular JIA whose joint pain is completely controlled on naproxen can have active T-cell-driven synovitis producing matrix metalloproteinases that degrade articular cartilage silently, because articular cartilage has no nerve fibers to report the damage. A child with enthesitis-related arthritis can have active anterior chamber inflammation producing posterior synechiae and beginning band keratopathy in both eyes without ever experiencing a red, painful, or photophobic eye, because pediatric JIA uveitis characteristically lacks the acute ciliary spasm that makes adult uveitis a symptomatic emergency. A child with systemic JIA whose disease has been quiet for two weeks on tocilizumab can develop macrophage activation syndrome from a rhinovirus and be heading toward hepatic failure and disseminated intravascular coagulation within twenty-four hours of what appears to be a mild fever.
Spanish for pediatric juvenile idiopathic arthritis clinic nurses begins with recognizing three structural gaps between what families observe about their child’s disease and what the clinical team is managing at the immunological and structural level. First: if the joint pain and swelling are controlled on naproxen and the child is playing normally, why is a weekly medication with liver monitoring requirements being added? Second: if the child has perfectly white, comfortable eyes and has never mentioned eye discomfort, why is an ophthalmology appointment every six months medically necessary? Third: if the disease is quiet and the child has been afebrile for two weeks on an immunosuppressive therapy, why does a mild fever mean a 911 call? Each answer requires making an invisible biological process visible — the gap between NSAID pain control and methotrexate-level structural protection in oligoarticular JIA, the asymptomatic nature of pediatric JIA uveitis, and the specific mechanism by which macrophage activation syndrome exploits the tocilizumab-blunted inflammatory response.
The three conversations in this post take place in Houston, San Antonio, and Dallas, in the outpatient pediatric rheumatology clinics of children’s hospitals serving primarily Spanish-speaking families. Each involves a family that is engaged, has maintained clinic appointments reliably, and is genuinely confused by a recommendation that appears to exceed what their observation of their child’s current state warrants. Each involves a bilingual nurse explaining the invisible mechanism in Spanish-English dialogue.
Scenario 1: Diego Vargas-Mendoza — Houston, Texas
Pediatric JIA nurse Ana Morales-García and the parents who cannot understand why methotrexate is needed when naproxen is already controlling joint pain
Diego is eight years old. He was born in Houston to Eduardo Vargas-Cruz, forty-two, an electrician, and Carmen Mendoza-Torres, thirty-nine, a teacher’s aide at an elementary school. Six months ago, Diego began limping on his left leg and complaining of knee stiffness in the mornings. His pediatrician noted left knee effusion with warmth, referred him to pediatric rheumatology, and the workup confirmed oligoarticular JIA: four joints involved at diagnosis (left knee most severely, right ankle, left wrist, right elbow), ESR 38 mm/hr, CRP 1.4 mg/L, ANA positive at 1:320, rheumatoid factor negative. He was started on naproxen 15 mg/kg/day in two divided doses.
Six months later, Diego’s results are dramatically improved. He reports no morning stiffness. The left knee effusion is clinically absent. He runs, plays soccer at recess, and Eduardo says Diego no longer asks to stay home from school. His ESR has fallen to 18 mm/hr. Today’s visit, the rheumatologist is recommending adding methotrexate 10 mg/m² weekly by subcutaneous injection, with baseline liver function tests and monthly monitoring labs.
Eduardo opens the conversation before the doctor has finished leaving the room: “Espera — necesito que nos expliquen bien esto. Diego está perfectamente bien con el naproxeno. No tiene dolor, no está inflamado, juega fútbol todos los días. ¿Por qué necesita ahora una inyección todas las semanas con análisis de sangre cada mes? Si el naproxeno está funcionando, ¿no es suficiente?”
(Wait — I need you to explain this to us well. Diego is perfectly fine on naproxen. He has no pain, no swelling, he plays soccer every day. Why does he need an injection every week now with blood tests every month? If naproxen is working, isn’t that enough?)
Carmen: “Leímos sobre el metotrexato — que puede afectar el hígado, que baja las defensas. Diego está bien ahora. Nos parece muy fuerte para un niño que está bien.”
(We read about methotrexate — that it can affect the liver, that it lowers defenses. Diego is well now. It seems very strong to us for a child who is well.)
Nurse Ana Morales-García pulls her chair close. “Esa preocupación tiene todo el sentido del mundo, y quiero responderla con cuidado porque el argumento que ustedes están haciendo es lógico. Diego está bien — eso es real. Pero hay una diferencia importante entre lo que el naproxeno hace y lo que no puede hacer en la artritis de Diego. Y esa diferencia es lo que hace que el metotrexato sea necesario ahora, exactamente porque Diego está respondiendo bien.”
(That concern makes complete sense, and I want to answer it carefully because the argument you are making is logical. Diego is well — that is real. But there is an important difference between what naproxen does and what it cannot do in Diego’s arthritis. And that difference is what makes methotrexate necessary now, precisely because Diego is responding well.)
Eduardo: “¿Qué quiere decir?”
(What do you mean?)
“El naproxeno es un antiinflamatorio que trabaja bloqueando una enzima llamada COX — esa enzima produce sustancias llamadas prostaglandinas que son las que producen dolor, calor, e inflamación en las articulaciones. Cuando el naproxeno bloquea esa enzima, el dolor mejora, la inflamación visible mejora. Lo que Diego siente mejora. Eso es lo que están viendo en casa. Pero el proceso que está produciendo la artritis de Diego no es solo las prostaglandinas. El proceso más profundo en la articulación de Diego son células del sistema inmune — un tipo de células llamadas células T — que están infiltrando la membrana de la articulación y produciendo proteínas inflamatorias. Esas proteínas inflamatorias, a su vez, están estimulando a otras células a producir enzimas que degradan el cartílago de la articulación directamente. Y eso el naproxeno no lo toca.”
(Naproxen is an anti-inflammatory that works by blocking an enzyme called COX — that enzyme produces substances called prostaglandins that are what produce pain, warmth, and inflammation in the joints. When naproxen blocks that enzyme, the pain improves, the visible inflammation improves. What Diego feels improves. That is what you are seeing at home. But the process that is producing Diego’s arthritis is not only the prostaglandins. The deeper process in Diego’s joint is immune cells — a type of cells called T cells — that are infiltrating the lining of the joint and producing inflammatory proteins. Those inflammatory proteins, in turn, are stimulating other cells to produce enzymes that degrade the cartilage of the joint directly. And that naproxen does not reach.)
Carmen: “¿Pero si Diego no tiene dolor, es que el cartílago está bien, ¿no?”
(But if Diego has no pain, it means the cartilage is fine, right?)
“Esa es exactamente la parte más importante que necesito explicarles, porque parece lógica y no lo es. El cartílago de las articulaciones — la capa que cubre los huesos donde se mueve la articulación — no tiene nervios. No tiene terminaciones nerviosas que puedan detectar cuando el cartílago se está desgastando y mandar una señal de dolor. El cartílago puede estar perdiendo grosor y estructura mientras Diego se siente completamente bien. Por eso muchos niños con la artritis que tiene Diego llegan a los diez u once años y, cuando se hace una resonancia magnética, hay daño en el cartílago que ocurrió durante los años en que se sentían bien en el naproxeno. Ese daño es permanente — el cartílago no se regenera.”
(That is exactly the most important part I need to explain to you, because it seems logical and it is not. The cartilage of the joints — the layer covering the bones where the joint moves — has no nerves. It has no nerve endings that can detect when the cartilage is wearing down and send a pain signal. The cartilage can be losing thickness and structure while Diego feels completely well. That is why many children with Diego’s arthritis arrive at age ten or eleven and, when an MRI is done, there is cartilage damage that occurred during the years they felt well on naproxen. That damage is permanent — cartilage does not regenerate.)
Eduardo leans forward. “¿Y eso está pasando ahora, mientras Diego se siente bien?”
(And that is happening now, while Diego feels well?)
“Eso es lo que los estudios muestran en la artritis pediátrica. Los análisis de Diego — la velocidad de sedimentación, la proteína C reactiva — han mejorado mucho. Pero esos análisis miden la inflamación general en el cuerpo, no miden directamente la actividad de las células T dentro de la articulación de la rodilla de Diego. Pueden estar relativamente normales mientras las células T dentro de la articulación siguen produciendo esas enzimas en cantidades más bajas. La resonancia magnética podiía ver eso, pero no hacemos resonancias todos los meses — usamos los análisis de sangre y la evaluación clínica como guía. Por eso las guías internacionales de artritis pediátrica recomiendan el metotrexato temprano en niños como Diego, que empezaron con cuatro articulaciones involucradas y con el ANA positivo: porque esa combinación indica un perfil de enfermedad que responde al naproxeno para los síntomas pero que tiene una probabilidad más alta de daño estructural silencioso sin metotrexato.”
(That is what studies show in pediatric arthritis. Diego’s tests — the sedimentation rate, the C-reactive protein — have improved a lot. But those tests measure general inflammation in the body, they do not directly measure the activity of T cells inside Diego’s knee joint. They can be relatively normal while the T cells inside the joint continue producing those enzymes in lower quantities. An MRI could see that, but we do not do MRIs every month — we use blood tests and clinical evaluation as a guide. That is why the international guidelines for pediatric arthritis recommend early methotrexate in children like Diego, who started with four joints involved and with ANA positive: because that combination indicates a disease profile that responds to naproxen for symptoms but has a higher probability of silent structural damage without methotrexate.)
Carmen: “¿Y el metotrexato puede llegar a esas células T?”
(And methotrexate can reach those T cells?)
“Sí. El metotrexato en las dosis que usamos para la artritis — que son mucho más bajas que las dosis de quimioterapia — funciona principalmente suprimiendo la activación de las células T en la membrana de la articulación. Lo hace a través de un mecanismo diferente al del naproxeno. El metotrexato produce la acumulación de una molécula dentro de las células inmunes que desencadena la liberación de adenosina — y la adenosina es una señal natural del cuerpo que apaga la activación de las células T. Cuando la activación de las células T se reduce, se reduce la producción de las proteínas inflamatorias, y con eso se reduce la producción de las enzimas que degradan el cartílago. En los estudios, los niños con artritis pediátrica tratados con metotrexato tienen significativamente menos daño en el cartílago en las resonancias a los dos y tres años que los niños que solo reciben antiinflamatorios.”
(Yes. Methotrexate at the doses we use for arthritis — which are much lower than chemotherapy doses — works primarily by suppressing T-cell activation in the joint lining. It does this through a different mechanism than naproxen. Methotrexate produces the accumulation of a molecule inside immune cells that triggers the release of adenosine — and adenosine is a natural signal of the body that turns off T-cell activation. When T-cell activation is reduced, the production of inflammatory proteins is reduced, and with that the production of the enzymes that degrade cartilage is reduced. In studies, children with pediatric arthritis treated with methotrexate have significantly less cartilage damage on MRI at two and three years than children who only receive anti-inflammatories.)
Eduardo: “¿Y los efectos secundarios en el hígado que leímos?”
(And the liver side effects we read about?)
“Son reales y por eso pedimos los análisis mensuales — para detectar cualquier elevación de enzimas hepáticas antes de que sea significativa. La elevación que ocurre es generalmente leve y transitoria, y la mayoría de las veces se resuelve ajustando la dosis o agregando ácido fólico, que es una vitamina que reduce los efectos secundarios del metotrexato. El riesgo de daño hepático serio con las dosis pediátricas de metotrexato — con el monitoreo que hacemos — es muy bajo y está bien documentado en decenas de miles de niños con artritis pediátrica. Lo que queremos evitar con el metotrexato — el daño al cartílago de Diego — tiene consecuencias a veinte y treinta años que son mucho más importantes para su calidad de vida que los efectos secundarios manejables del metotrexato con monitoreo adecuado.”
(They are real and that is why we order monthly tests — to detect any elevation of liver enzymes before it becomes significant. The elevation that occurs is generally mild and transient, and most of the time it resolves by adjusting the dose or adding folic acid, which is a vitamin that reduces methotrexate side effects. The risk of serious liver damage with pediatric doses of methotrexate — with the monitoring we do — is very low and is well documented in tens of thousands of children with pediatric arthritis. What we want to prevent with methotrexate — damage to Diego’s cartilage — has consequences at twenty and thirty years that are much more important for his quality of life than the manageable side effects of methotrexate with adequate monitoring.)
Carmen: “O sea que el naproxeno controla el dolor pero no está protegiendo el cartílago.”
(So naproxen controls pain but is not protecting the cartilage.)
“Exactamente. Esa es la diferencia. El naproxeno controla los síntomas que Diego siente. El metotrexato va al proceso inmunológico que está produciendo el daño que Diego no siente. Las dos cosas son reales — el control del dolor y la protección del cartílago. Pero necesitan medicamentos diferentes porque actúan en niveles diferentes de la enfermedad. La meta del tratamiento de Diego no es solo que no tenga dolor hoy — es que cuando Diego tenga treinta años, sus rodillas y sus tobillos funcionen normalmente.”
(Exactly. That is the difference. Naproxen controls the symptoms Diego feels. Methotrexate goes to the immunological process producing the damage Diego does not feel. Both things are real — pain control and cartilage protection. But they need different medications because they act at different levels of the disease. The goal of Diego’s treatment is not only that he has no pain today — it is that when Diego is thirty years old, his knees and ankles function normally.)
Eduardo nods slowly. “No lo habíamos pensado así — que controlar el dolor y proteger la articulación son dos cosas diferentes.”
(We had not thought about it that way — that controlling pain and protecting the joint are two different things.)
“En la artritis pediátrica, lo son. Y eso es algo que el cuerpo de Diego no puede avisarles porque el cartílago no duele cuando se desgasta. Por eso estamos aquí — para hacer esa distinción por ustedes y tomar decisiones de tratamiento antes de que el daño invisible llegue a ser visible.”
(In pediatric arthritis, they are. And that is something Diego’s body cannot tell you because cartilage does not hurt when it wears down. That is why we are here — to make that distinction for you and make treatment decisions before the invisible damage becomes visible.)
Scenario 2: Sofía Méndez-Ramírez — San Antonio, Texas
Pediatric JIA nurse Isabel Torres-Herrera and the parents who cannot understand why their daughter with no eye symptoms needs slit-lamp ophthalmology every six months
Sofía is ten years old. She lives in San Antonio with her parents, Alejandro Méndez-Cruz, forty-four, a plumber, and Rosa Ramírez-Vega, forty-one, a home health aide. Eight months ago, Sofía began complaining of knee pain after sports and stiffness at her left hip in the mornings that lasted thirty minutes. Her workup confirmed enthesitis-related arthritis: HLA-B27 positive, bilateral patellar tendon enthesitis, left hip pain with restricted internal rotation, sacroiliac joint tenderness on physical exam. She was started on naproxen 15 mg/kg/day in two divided doses and referred to physical therapy.
Sofía has never had an eye complaint in her life. Her vision is 20/20 in both eyes at her last well-child visit. Her eyes are white and comfortable. She has never mentioned photophobia, eye pain, blurred vision, or redness to either parent or to any provider. Today’s visit, the rheumatologist is recommending that Sofía be seen by a pediatric ophthalmologist for a slit-lamp examination, to be repeated every six months.
Alejandro responds with visible confusion. “Sofía nunca ha tenido ningún problema en los ojos. Nunca ha dicho que le duelen los ojos, que los tiene rojos, que no ve bien. ¿Por qué necesita ir al oftálmo si no tiene nada en los ojos? ¿No es suficiente con que nos diga si le molestan?”
(Sofía has never had any eye problem. She has never said her eyes hurt, that they are red, that she doesn’t see well. Why does she need to go to the ophthalmologist if she has nothing in her eyes? Isn’t it enough for her to tell us if they bother her?)
Rosa: “La última revisión de visión en la escuela fue perfecta. Si hubiera algo en los ojos, lo notaríamos nosotros o ella lo sentiría, ¿no?”
(The last vision check at school was perfect. If there were something in the eyes, we would notice it or she would feel it, right?)
Nurse Isabel Torres-Herrera sits down and addresses both parents directly. “Esa lógica es completamente correcta para la mayoría de las enfermedades de los ojos. El problema es que la inflamación de los ojos que está asociada con la artritis de Sofía — que se llama uveítis — es completamente diferente a la inflamación de los ojos que la mayoría de las personas conoce. Cuando un adulto tiene uveítis, el ojo está rojo, duele, y es muy sensible a la luz. Ese es el tipo de uveítis que hace que la persona vaya al médico rápidamente. La uveítis de los niños con la artritis de Sofía es completamente diferente: no produce ojo rojo, no produce dolor, no produce sensibilidad a la luz. El ojo puede estar completamente blanco y cómodo mientras hay inflamación activa dentro del ojo.”
(That logic is completely correct for most eye diseases. The problem is that the eye inflammation associated with Sofía’s arthritis — called uveitis — is completely different from the eye inflammation most people know. When an adult has uveitis, the eye is red, it hurts, and it is very sensitive to light. That is the type of uveitis that makes the person go to the doctor quickly. The uveitis of children with Sofía’s arthritis is completely different: it does not produce a red eye, it does not produce pain, it does not produce light sensitivity. The eye can be completely white and comfortable while there is active inflammation inside it.)
Alejandro: “¿Por qué es diferente en los niños?”
(Why is it different in children?)
“En los adultos, la uveítis es normalmente aguda e intensa: la inflamación llega rápido y en grandes cantidades, y produce un espasmo del músculo ciliar — un músculo dentro del ojo — que es lo que produce el dolor intenso y la sensibilidad a la luz. En los niños con la artritis que tiene Sofía, la inflamación es crónica y lenta — ocurre durante meses sin llegar a la intensidad que produce ese espasmo. Por eso el ojo no duele. Pero la inflamación crónica y lenta puede producir daños igual de graves. Lo que hace en el ojo durante meses de inflamación sin tratamiento es: primero, produce adherencias entre el iris — la parte coloreada del ojo — y el cristalino, que está detrás. Esas adherencias se llaman sinequias, y limitan el movimiento de la pupila. Si la pupila no puede abrirse bien, puede producir presión dentro del ojo. Segundo, deposita calcio en la córnea — la capa transparente del frente del ojo — formando una banda blanquecina que puede extenderse hasta el centro del ojo y opacar la visión de manera permanente. Tercero, puede elevar la presión dentro del ojo y dañar el nervio óptico. Todo eso puede ocurrir mientras los ojos de Sofía se ven perfectamente blancos y cómodos y ella no siente nada.”
(In adults, uveitis is usually acute and intense: the inflammation arrives quickly and in large quantities, and produces a spasm of the ciliary muscle — a muscle inside the eye — which is what produces the intense pain and light sensitivity. In children with Sofía’s arthritis, the inflammation is chronic and slow — it occurs for months without reaching the intensity that produces that spasm. That is why the eye does not hurt. But the chronic, slow inflammation can produce equally serious damage. What it does in the eye during months of inflammation without treatment is: first, it produces adhesions between the iris — the colored part of the eye — and the crystalline lens, which is behind it. Those adhesions are called synechiae, and they limit pupil movement. If the pupil cannot open well, it can produce pressure inside the eye. Second, it deposits calcium in the cornea — the transparent layer at the front of the eye — forming a whitish band that can extend toward the center of the eye and opacify vision permanently. Third, it can raise the pressure inside the eye and damage the optic nerve. All of that can happen while Sofía’s eyes look perfectly white and comfortable and she feels nothing.)
Rosa: “¿Y la prueba de visión normal en la escuela no detecta eso?”
(And the normal vision test at school does not detect that?)
“No — y ese es el punto más importante. La prueba de visión mide cuánto puede ver Sofía — si puede leer la línea de letras pequeñas. No puede detectar la inflamación dentro de la cámara del ojo. Para ver esa inflamación — las células inflamatorias que flotan en el líquido dentro del ojo, el inicio de las adherencias, el inicio del depósito de calcio en la córnea — se necesita un instrumento especial que solo el oftalmólogo tiene: el biomicroscopio de lámpara de hendidura. Es un microscopio de alta potencia que ilumina y magnifica la cámara del ojo directamente. Con ese instrumento, el oftalmólogo puede ver las células inflamatorias dentro del ojo mucho antes de que esas células hayan producido el daño que afectaría la visión. Si encontramos inflamación activa, la tratamos con colirios de corticosteroides — gotas que se aplican en el ojo — y el daño se puede prevenir. Si esperamos a que Sofía vea menos bien o sienta molestias, generalmente significa que el daño ya está avanzado y es más difícil de revertir.”
(No — and that is the most important point. The vision test measures how much Sofía can see — if she can read the line of small letters. It cannot detect inflammation inside the eye chamber. To see that inflammation — the inflammatory cells floating in the fluid inside the eye, the beginning of the adhesions, the beginning of calcium deposit in the cornea — a special instrument is needed that only the ophthalmologist has: the slit-lamp biomicroscope. It is a high-power microscope that illuminates and magnifies the eye chamber directly. With that instrument, the ophthalmologist can see the inflammatory cells inside the eye long before those cells have produced the damage that would affect vision. If we find active inflammation, we treat it with corticosteroid eye drops — drops applied to the eye — and the damage can be prevented. If we wait for Sofía to see less well or feel discomfort, it generally means the damage is already advanced and harder to reverse.)
Alejandro: “¿Cuántos niños con la artritis de Sofía tienen este problema en los ojos?”
(How many children with Sofía’s arthritis have this eye problem?)
“En los niños con artritis relacionada a la entesitis — que es la artritis de Sofía — y con el gen HLA-B27 positivo, el riesgo de uveítis es del diez al veinte por ciento a lo largo de la vida de la enfermedad. No es un riesgo pequeño, y el HLA-B27 que tiene Sofía es uno de los factores de riesgo más fuertes para este tipo de uveítis. Las guías internacionales para artritis pediátrica recomiendan la revisión de lámpara de hendidura cada seis meses exactamente porque el riesgo es suficientemente alto como para justificar la vigilancia, y los daños que ocurren cuando la uveítis no se detecta son suficientemente severos como para que la detección temprana sea crítica. En la mayoría de las visitas, el oftalmólogo no va a encontrar nada — y eso es la buena noticia que esperamos obtener. Pero en la visita en que sí encuentre algo, será la diferencia entre tratarlo con gotas de ojo y prevenir el daño, o encontrarlo cuando ya afectó la visión de Sofía de manera permanente.”
(In children with enthesitis-related arthritis — which is Sofía’s arthritis — and with HLA-B27 positive, the risk of uveitis is 10 to 20 percent over the course of the disease. It is not a small risk, and the HLA-B27 Sofía has is one of the strongest risk factors for this type of uveitis. International guidelines for pediatric arthritis recommend slit-lamp examination every six months precisely because the risk is high enough to justify surveillance, and the damage that occurs when uveitis is not detected is severe enough for early detection to be critical. In most visits, the ophthalmologist will not find anything — and that is the good news we hope to get. But in the visit where something is found, it will be the difference between treating it with eye drops and preventing damage, or finding it when it has already affected Sofía’s vision permanently.)
Rosa sits quietly for a moment. “Entonces los ojos pueden estar enfermos aunque se vean sanos.”
(So the eyes can be sick even though they look healthy.)
“Con la artritis de Sofía, sí. Eso es exactamente lo que hace que este tipo de uveítis sea tan peligroso sin vigilancia: que no avisa. El ojo rojo y doloroso en el adulto avisa — la persona va al médico. Los ojos silenciosamente inflamados de un niño con artritis pediátrica no avisan. Por eso la vigilancia no depende de que Sofía sienta algo — depende de que el oftalmólogo mire adentro del ojo con el instrumento adecuado, en el intervalo que las guías recomiendan, para detectar lo que Sofía no puede sentir.”
(With Sofía’s arthritis, yes. That is exactly what makes this type of uveitis so dangerous without surveillance: it does not give warning. The red, painful eye in an adult gives warning — the person goes to the doctor. The silently inflamed eyes of a child with pediatric arthritis do not give warning. That is why surveillance does not depend on Sofía feeling something — it depends on the ophthalmologist looking inside the eye with the right instrument, at the interval the guidelines recommend, to detect what Sofía cannot feel.)
Scenario 3: Isabella García-Torres — Dallas, Texas
Pediatric JIA nurse Claudia Vásquez-Morales and the parents who cannot understand why a mild fever means a 911 call when their daughter has been quiet on tocilizumab for two weeks
Isabella is twelve years old. She lives in Dallas with her parents, Carmen García-Morales, forty-two, a grocery store cashier, and Roberto Torres-Cruz, forty-five, a construction worker. Fourteen months ago, Isabella developed daily fevers spiking to 39.8°C in the late afternoon, a faint salmon-colored rash that appeared with the fever and faded as it broke, and progressive pain and swelling in her wrists and ankles. Her ferritin at presentation was 14,500 ng/mL. MRI showed bilateral wrist and ankle synovitis. Echocardiogram showed a small pericardial effusion. She was diagnosed with systemic juvenile idiopathic arthritis.
She was started on naproxen, then tocilizumab 8 mg/kg intravenously every four weeks after inadequate response to naproxen alone. Within six weeks of tocilizumab initiation, the fevers resolved, the rash disappeared, and joint pain improved significantly. Now, fourteen months after diagnosis, Isabella has been afebrile for two weeks. Her ferritin has trended down to 520 ng/mL. Her joints are quiet. The parents consider the disease well controlled.
At today’s clinic visit, the rheumatologist gives a specific instruction before the parents leave: if Isabella develops any fever at all — any temperature above 38.0°C — or if the salmon rash reappears, they must go directly to the emergency department, not call the office, not wait until morning, and not observe at home. Carmen and Roberto are confused.
Carmen: “¿Por qué el hospital de emergencias? Si Isa tiene un catarro y un poco de fiebre, ¿no podemos darle Tylenol y llamar a la clínica el lunes?”
(Why the emergency hospital? If Isa has a cold and a little fever, can’t we give her Tylenol and call the clinic on Monday?)
Roberto: “Lleva dos semanas muy bien — sin fiebre, sin dolor, casi normal. Parece mucho que una fiebre pequeña sea una emergencia ahora.”
(She has had two weeks very well — no fever, no pain, almost normal. It seems like a lot that a small fever is an emergency now.)
Nurse Claudia Vásquez-Morales sits down with both parents. “Tienen razón en que Isabella está muy bien ahora y en que dos semanas sin fiebre es un muy buen signo. Y entiendo perfectamente por qué una fiebre pequeña no parece una emergencia — para la gran mayoría de los niños, no lo sería. Pero Isabella tiene una condición que hace que la fiebre sea una señal diferente para ella que para otros niños. Necesito explicarles por qué, porque quiero que entiendan la razón de esta instrucción — no solo que la sigan.”
(You are right that Isabella is very well now and that two weeks without fever is a very good sign. And I completely understand why a small fever does not seem like an emergency — for the great majority of children, it would not be. But Isabella has a condition that makes fever a different signal for her than for other children. I need to explain to you why, because I want you to understand the reason for this instruction — not just to follow it.)
Carmen: “Explíquenos.”
(Explain it to us.)
“La artritis sistémica de Isabella — la artritis con fiebre, el sarpullido, la inflamación del corazón que tuvieron al principio — tiene una complicación grave que se llama síndrome de activación macrofágica. Lo llamamos SAM para abreviar. El SAM ocurre en aproximadamente el diez al quince por ciento de los niños con la artritis sistémica de Isabella a lo largo de su enfermedad. Es una complicación donde el sistema inmune entra en una espiral de activación extrema que no puede detenerse solo — el resultado es inflamación masiva que daña el hígado, los riñones, la coagulación de la sangre, y puede llegar al cerebro.”
(Isabella’s systemic arthritis — the arthritis with fever, the rash, the heart inflammation they had at the beginning — has a serious complication called macrophage activation syndrome. We call it MAS for short. MAS occurs in approximately 10 to 15 percent of children with Isabella’s systemic arthritis over the course of their disease. It is a complication where the immune system enters a spiral of extreme activation that it cannot stop on its own — the result is massive inflammation that damages the liver, kidneys, blood clotting, and can reach the brain.)
Roberto: “¿Pero si el tocilizumab lo está controlando?”
(But if tocilizumab is controlling it?)
“El tocilizumab controla la artritis sistémica de Isabella muy bien — eso es lo que estamos viendo con las dos semanas sin fiebre y las articulaciones tranquilas. Pero el SAM no es lo mismo que la artritis sistémica. El SAM puede ser desencadenado por una infección viral — una gripe común, un resfriado por adenovirus, cualquier virus respiratorio que para otro niño dura tres días. El tocilizumab no previene el SAM. Lo que hace el SAM en el cuerpo es diferente de lo que hace la artritis sistémica, y el tocilizumab no bloquea ese proceso completamente.”
(Tocilizumab controls Isabella’s systemic arthritis very well — that is what we are seeing with two weeks without fever and quiet joints. But MAS is not the same as systemic arthritis. MAS can be triggered by a viral infection — a common flu, a cold from adenovirus, any respiratory virus that for another child lasts three days. Tocilizumab does not prevent MAS. What MAS does in the body is different from what systemic arthritis does, and tocilizumab does not fully block that process.)
Carmen: “¿Y cómo empieza el SAM?”
(And how does MAS start?)
“Generalmente empieza exactamente como parece: fiebre, a veces el sarpullido color salmón de Isabella que ven cuando la artritis está activa, cansancio. En ese primer momento, parece un virus común o un brote de la artritis. El problema es lo que pasa en las siguientes veinticuatro a cuarenta y ocho horas sin tratamiento. En ese tiempo, los niveles de ferritina — una proteína que el cuerpo produce cuando hay inflamación severa — pueden subir de 500 a 5,000 o a 50,000. Las plaquetas empiezan a bajar — las plaquetas son las células que ayudan a la sangre a coagularse. Los glóbulos rojos empiezan a bajar. El hígado empieza a verse afectado. La coagulación de la sangre se desordena. Puede llegar a fallo de múltiples órganos en dos días. Ese es el tiempo entre “fiebre que parece un catarro” y “emergencia en la UCI”.”
(Generally it starts exactly as it seems: fever, sometimes the salmon-colored rash of Isabella’s that you see when the arthritis is active, fatigue. In that first moment, it looks like a common virus or an arthritis flare. The problem is what happens in the next twenty-four to forty-eight hours without treatment. In that time, ferritin levels — a protein the body produces when there is severe inflammation — can rise from 500 to 5,000 or 50,000. Platelets start to fall — platelets are the cells that help blood clot. Red blood cells start to fall. The liver starts to be affected. Blood clotting becomes disordered. It can reach multi-organ failure in two days. That is the time between “fever that looks like a cold” and “emergency in the ICU.”)
Roberto looks alarmed. “¿Y cómo sabemos si es el SAM o un catarro normal?”
(And how do we know if it is MAS or a normal cold?)
“Esa es exactamente la pregunta correcta, y la respuesta es: no lo pueden saber en casa. Lo que necesitamos para distinguirlos son análisis de sangre específicos: la ferritina — que en el SAM sube drámicamente; el conteo de glóbulos — que en el SAM empieza a bajar; las enzimas del hígado; la coagulación de la sangre. Esos resultados solo los podemos obtener en el hospital. Y necesitamos obtenerlos rápido — porque si es el SAM, el tratamiento tiene que empezar en horas, no en días.”
(That is exactly the right question, and the answer is: you cannot know at home. What we need to distinguish them are specific blood tests: ferritin — which in MAS rises dramatically; blood cell count — which in MAS starts to fall; liver enzymes; blood clotting. Those results we can only get at the hospital. And we need to get them quickly — because if it is MAS, treatment must start in hours, not days.)
Carmen: “¿Y si esperamos al lunes y era el SAM?”
(And if we wait until Monday and it was MAS?)
“En ese tiempo, el SAM puede progresar de manera significativa. El tratamiento del SAM — corticosteroides en dosis muy altas por vía intravenosa, y a veces medicamentos adicionales para bloquear la inflamación — tiene que empezar mientras el proceso todavía es controlable. Si esperamos a que los síntomas sean claramente graves — Isabella con la presión muy baja, sangrando, con el hígado fallando — el tratamiento es mucho más difícil y los resultados son peores.”
(In that time, MAS can progress significantly. The treatment of MAS — corticosteroids at very high doses intravenously, and sometimes additional medications to block the inflammation — must start while the process is still controllable. If we wait until the symptoms are clearly serious — Isabella with very low blood pressure, bleeding, with the liver failing — treatment is much more difficult and outcomes are worse.)
Roberto: “Pero dijeron que el tocilizumab podía hacer que la fiebre fuera más baja de lo que realmente está pasando.”
(But you said tocilizumab could make the fever lower than what is really happening.)
“Exactamente — y eso es lo que hace que la situación sea especialmente importante de entender. El tocilizumab bloquea una proteína llamada interleucina-6, que es parte de la respuesta de fiebre del cuerpo. Cuando el cuerpo combate una infección o una inflamación, la interleucina-6 sube y esa es parte de la señal que produce la fiebre alta. Con el tocilizumab bloqueando esa señal, la fiebre de Isabella puede ser más baja de lo que sería sin el medicamento, aunque el proceso inflamatorio interno sea grave. También, el tocilizumab suprime la proteína C reactiva — otro análisis que normalmente sube en las infecciones. Con el tocilizumab, ese análisis puede estar bajo aunque haya algo serio ocurriendo. Entonces si Isabella tiene 38.2 de fiebre y parece relativamente bien, el tocilizumab puede estar enmascaran do algo más grave que lo que la temperatura y la apariencia muestran. Por eso la ferritina — que el tocilizumab no suprime de la misma manera — es el análisis que necesitamos verificar en el hospital.”
(Exactly — and that is what makes the situation especially important to understand. Tocilizumab blocks a protein called interleukin-6, which is part of the body’s fever response. When the body fights an infection or inflammation, interleukin-6 rises and that is part of the signal that produces high fever. With tocilizumab blocking that signal, Isabella’s fever can be lower than it would be without the medication, even if the internal inflammatory process is serious. Also, tocilizumab suppresses C-reactive protein — another test that normally rises with infections. With tocilizumab, that test can be low even if something serious is happening. So if Isabella has 38.2 of fever and seems relatively well, tocilizumab may be masking something more serious than the temperature and appearance show. That is why ferritin — which tocilizumab does not suppress in the same way — is the test we need to verify at the hospital.)
Carmen takes a deep breath. “O sea que la fiebre de Isa no es una fiebre normal porque el medicamento puede estar escondiendo lo que está pasando de verdad.”
(So Isa’s fever is not a normal fever because the medication may be hiding what is really happening.)
“Exactamente. Para cualquier otro niño, una fiebre de 38.2 es probablemente un virus de tres días y pueden esperar en casa. Para Isabella, en este medicamento, con esta artritis, necesitamos los análisis de sangre específicos para saber con certeza qué está pasando. El noventa por ciento de las veces, los análisis van a mostrar que es una infección viral simple y Isabella puede volver a casa. Pero el diez por ciento de las veces — y no podemos saber desde casa cuál es cuál — los análisis van a mostrar que el SAM está empezando y necesitamos actuar inmediatamente. Por eso la instrucción es ir siempre al hospital, llevar la lista de medicamentos de Isabella, y pedir los análisis específicos del SAM. Ese es el protocolo que protege a Isabella.”
(Exactly. For any other child, a fever of 38.2 is probably a three-day virus and they can wait at home. For Isabella, on this medication, with this arthritis, we need the specific blood tests to know with certainty what is happening. Ninety percent of the time, the tests will show it is a simple viral infection and Isabella can return home. But ten percent of the time — and we cannot know from home which is which — the tests will show that MAS is starting and we need to act immediately. That is why the instruction is to always go to the hospital, bring Isabella’s medication list, and ask for the specific MAS tests. That is the protocol that protects Isabella.)
Roberto: “¿Qué análisis pedimos cuando llegamos?”
(What tests do we ask for when we arrive?)
“Cuando llegan al hospital de emergencias, digan exactamente esto: ‘Mi hija tiene artritis sistémica juvenil, está en tocilizumab, y tiene fiebre. Queremos descartar síndrome de activación macrofágica.’ Eso indica al equipo de emergencias lo que necesitan. Los análisis que necesitan hacer son: ferritina, hemograma completo con plaquetas, transaminasas hepáticas, fibrinógeno, dímero D, y trigléridos. Con esos resultados, el equipo puede saber en una o dos horas si hay un SAM comenzando. Vamos a darles una tarjeta con esa información escrita para que la tengan en la billetera.”
(When you arrive at the emergency hospital, say exactly this: ‘My daughter has systemic juvenile idiopathic arthritis, she is on tocilizumab, and she has fever. We want to rule out macrophage activation syndrome.’ That indicates to the emergency team what they need. The tests they need to do are: ferritin, complete blood count with platelets, liver transaminases, fibrinogen, D-dimer, and triglycerides. With those results, the team can know in one to two hours if there is a beginning MAS. We are going to give you a card with that information written down to keep in your wallet.)
Carmen and Roberto both nod. Carmen says quietly: “Nunca pensamos que una fiebre en Isa era diferente a la de otro niño. Ahora entendemos por qué lo es.”
(We never thought that a fever in Isa was different from another child’s. Now we understand why it is.)
Frequently asked questions
How do pediatric JIA clinic nurses explain to Spanish-speaking parents why methotrexate is needed when NSAIDs are already controlling their child’s joint pain?
The explanation requires distinguishing what NSAIDs accomplish (suppression of COX-1/COX-2-mediated prostaglandin E2 synthesis — reducing joint pain, warmth, and swelling) from what they do not accomplish (suppression of the CD4+ T-cell-driven synovial immune process that produces matrix metalloproteinases directly degrading articular cartilage and drives RANKL-mediated osteoclast activation eroding periarticular bone). Articular cartilage is avascular and aneural: it has no blood supply and no pain nerve fibers. Cartilage degradation produces no pain signal directly — a child can have active enzyme-mediated cartilage damage while feeling completely well on NSAIDs. The IL-1, IL-6, IL-17, and TNF-alpha produced by the T-cell-infiltrated synovium drive MMP-1, MMP-3, and MMP-13 secretion from synoviocytes and chondrocytes, degrading type II collagen and aggrecan independently of prostaglandin synthesis. Methotrexate at anti-inflammatory doses works via AICAR accumulation and adenosine-mediated A2A/A2B receptor signaling that suppresses T-cell activation and pro-inflammatory cytokine production — suppressing the immunological source of cartilage destruction that NSAIDs cannot reach. Multiple pediatric JIA trials and CARRA registry data show that methotrexate achieves clinical inactive disease in approximately 70 percent of oligoarticular JIA patients and that inactive disease correlates with structural cartilage protection on MRI. The key Spanish frame: el naproxeno controla el dolor; el metotrexato protege el cartílago que no tiene nervios para avisar cuando se está dañando.
How do pediatric JIA clinic nurses explain to Spanish-speaking parents why their child with enthesitis-related arthritis needs regular slit-lamp ophthalmology when the child has no eye symptoms?
The explanation requires distinguishing how adult uveitis typically presents (acute ciliary spasm producing a red, painful, photophobic eye that drives rapid medical evaluation) from how JIA-associated anterior uveitis in children typically presents (chronic, insidious, nongranulomatous anterior chamber inflammation that produces no acute ciliary spasm, no redness, no pain, and no visual change detectable by the child or family). Between 70 and 90 percent of children with JIA-associated uveitis have no visual complaints at the time uveitis is first detected on slit-lamp examination. Despite clinical silence, the inflammation produces posterior synechiae (iris-lens adhesions limiting pupil mobility, with risk of angle-closure glaucoma), band keratopathy (calcium deposition in Bowman’s corneal layer extending centrally to opacify the visual axis permanently), secondary glaucoma (from trabecular meshwork dysfunction and pupil block), and cataract — all causing irreversible vision loss. The slit-lamp biomicroscope is the only instrument that detects anterior chamber cells, flare, early synechiae, and early band keratopathy before structural damage reaches visual impairment. Visual acuity testing, school vision checks, and gross inspection cannot detect anterior chamber inflammation. ACR/CARRA guidelines recommend slit-lamp every six months for HLA-B27-positive ERA patients. The key Spanish frame: la inflamación en los ojos de los niños con artritis pediátrica no produce ojo rojo ni dolor; el ojo puede estar inflamado con los ojos completamente blancos y cómodos; el daño puede ser permanente; solo la lámpara de hendidura puede verlo antes de que sea tarde.
How do pediatric JIA clinic nurses explain to Spanish-speaking parents why any fever in a child with systemic JIA on tocilizumab requires immediate emergency department evaluation?
The explanation requires two components: the clinical trajectory of macrophage activation syndrome (MAS) and the specific effect of tocilizumab on the early warning signals. MAS is a secondary hemophagocytic lymphohistiocytosis variant complicating 10 to 15 percent of systemic JIA patients, driven by NK-cell cytolytic dysfunction and IL-18 hypersecretion producing a runaway IFN-gamma/macrophage activation loop. Any intercurrent viral infection can trigger MAS regardless of how well the underlying sJIA is controlled. The clinical timeline: Day 1, fever and possible rash reappearance (looks like mild viral illness or sJIA flare); Day 2 to 3, ferritin surging toward 5,000 to 50,000 ng/mL, platelets falling, hemoglobin falling, liver enzymes rising; Day 3 to 5, DIC, fulminant hepatic failure, encephalopathy, multi-organ failure. This 24 to 48-hour window from apparent mild illness to critical condition is what makes same-day hospital evaluation non-negotiable. Tocilizumab compounds the danger by blunting two key early warning signals: it blocks IL-6, which is part of the hypothalamic fever-generating pathway, so a child with early MAS on tocilizumab may have blunted fever amplitude (38.2°C instead of 39.8°C, appearing less ill than the internal inflammatory state warrants); and it suppresses CRP synthesis, making the first-look blood test falsely reassuring. Ferritin — not suppressed equivalently by IL-6 blockade — is the key early MAS biomarker. This requires a stat hospital blood draw, not a home thermometer. The emergency instruction card: ferritin, CBC, LFTs, fibrinogen, D-dimer, triglycerides; tell the ED team “rule out MAS in systemic JIA on tocilizumab.”
What are the key clinical Spanish phrases for explaining methotrexate, uveitis screening, and macrophage activation syndrome fever emergencies to Spanish-speaking families in the pediatric JIA clinic?
For methotrexate in JIA despite pain control: “El naproxeno controla el dolor, pero no llega al proceso inmunológico que está dañando el cartílago de las articulaciones” (naproxen controls pain, but does not reach the immunological process damaging joint cartilage). “El cartílago no tiene nervios — cuando se daña, no duele, y Diego puede sentirse bien mientras el cartílago pierde estructura” (cartilage has no nerves — when it is damaged, it does not hurt, and Diego can feel well while cartilage loses structure). “El metotrexato suprime las células T que están produciendo las enzimas que degradan el cartílago — es el que puede proteger las articulaciones a largo plazo” (methotrexate suppresses the T cells producing the enzymes that degrade cartilage — it is what can protect joints long-term). For asymptomatic uveitis screening: “La inflamación en los ojos de los niños con la artritis de Sofía no produce ojo rojo ni dolor — los ojos pueden estar inflamados y verse completamente normales” (eye inflammation in children with Sofía’s arthritis does not produce a red eye or pain — the eyes can be inflamed and look completely normal). “Si esa inflamación no se detecta, puede dejar cicatrices dentro del ojo que dañan la vista de manera permanente, sin que Sofía sienta nada” (if that inflammation is not detected, it can leave scars inside the eye that permanently damage vision, without Sofía feeling anything). “La lámpara de hendidura del oftalmólogo es el único instrumento que puede ver esa inflamación dentro del ojo antes de que cause daño” (the ophthalmologist’s slit-lamp is the only instrument that can see that inflammation inside the eye before it causes damage). For MAS fever emergency: “Si Isabella tiene fiebre, tienen que ir directamente al hospital de emergencias — no esperar a ver si mejora” (if Isabella has fever, you must go directly to the emergency hospital — do not wait to see if it improves). “La artritis sistémica de Isabella tiene una complicación que puede progresar de fiebre a fallo de órganos en 24 a 48 horas” (Isabella’s systemic arthritis has a complication that can progress from fever to organ failure in 24 to 48 hours). “El tocilizumab puede hacer que la fiebre parezca más baja de lo que está pasando adentro — por eso una fiebre pequeña en Isabella no es lo mismo que en otro niño” (tocilizumab can make the fever appear lower than what is happening inside — that is why a small fever in Isabella is not the same as in another child). “Digan en el hospital: mi hija tiene artritis sistémica juvenil y toma tocilizumab, queremos descartar síndrome de activación macrofágica” (say at the hospital: my daughter has systemic juvenile idiopathic arthritis and takes tocilizumab, we want to rule out macrophage activation syndrome).
What are the most important communication challenges specific to Spanish-speaking families in the pediatric JIA outpatient clinic that standard handouts do not address?
Three structural disconnects drive the communication challenges in the pediatric JIA outpatient clinic. The first disconnect is between the family’s direct experience that NSAIDs are working — the child’s joint pain is controlled, the child is functioning normally, the family’s daily quality of life has normalized — and the clinical recommendation to add a second medication with monitoring requirements. The family is not wrong that NSAIDs are working; NSAIDs are working at the level the family can observe. The difficulty is that the level they can observe (symptom control) and the level at risk (structural joint protection) are governed by different biological mechanisms, and the mechanism producing structural damage produces no observable signal in the family’s domain of observation. A nurse who can make the second biological level visible — explaining that articular cartilage has no nerves and therefore cannot signal its own degradation, and that the enzyme-producing T-cell synovitis operates independently of the prostaglandin pathway NSAIDs block — gives the family a reason to accept methotrexate that their successful NSAID experience cannot provide. The second disconnect is between the family’s model of eye disease (built from common experience that an eye problem produces visible symptoms) and the specific biology of pediatric JIA uveitis, which is the important exception to that model. This exception is not intuitive, and it is not addressed by handouts that describe “uveitis” without specifying that the pediatric form lacks the symptomatic presentation the family would recognize. A nurse who can explain why pediatric JIA uveitis is asymptomatic — not just assert that screening matters but explain the mechanistic reason the condition lacks the symptoms adults associate with eye inflammation — gives the family a framework that makes the screening make sense rather than seeming like excess caution. The family that understands this will keep the ophthalmology appointments even during years when all examinations are negative, because they understand that a negative examination is a clinically meaningful reassurance that requires the examination to obtain. The third disconnect is the most acutely dangerous, and it operates at the intersection of pharmacology and family emergency-response training. Families of children on tocilizumab have learned to interpret their child’s inflammatory signals through the lens of NSAID/tocilizumab response — if the fever is low and the child seems okay, the disease must be quiet. This interpretive framework is dangerous in the MAS context specifically because tocilizumab blunts the two signals — fever amplitude and CRP — that would otherwise make early MAS look like a medical emergency. A nurse who can explain not just that fever in this child is an emergency but why this child’s fever is informationally different from another child’s fever — specifically, that tocilizumab’s IL-6 blockade reduces the fever and CRP that are the family’s habitual proxy measures of inflammatory severity, so a 38.2°C fever in a tocilizumab-treated sJIA child can represent a greater internal inflammatory state than a 40°C fever in an untreated child — gives the family the pharmacological logic that makes the emergency instruction make sense rather than seeming disproportionate. The family that understands this will go to the ED at 38.2°C rather than watching at home until the temperature reaches 40°C — and that behavioral difference is the difference between catching MAS while treatable and arriving in multi-organ failure.
Pediatric juvenile idiopathic arthritis clinic nursing requires holding three biological frameworks simultaneously — the gap between NSAID pain control and structural joint protection, the asymptomatic natural history of pediatric JIA uveitis, and the pharmacologically modified emergency signal in systemic JIA on tocilizumab — and translating each into a bilingual conversation that builds the family’s understanding from their direct experience rather than overwriting it. The family that leaves Diego’s appointment understanding that cartilage has no pain fibers will maintain methotrexate adherence during the years Diego plays soccer and the medication seems unnecessary. The family that understands why Sofía’s uveitis produces no symptoms in children will attend every ophthalmology appointment even when each visit is negative. The family that understands why tocilizumab makes Isabella’s fever an informationally different signal than any other child’s fever will go to the emergency department at 38.2°C instead of watching and waiting until the MAS is in its third day.
In all three conversations, the families had built accurate mental models of their child’s disease at the level of observable events — based on what they saw, what they felt, what their prior clinical experiences confirmed — and arrived at a deeper understanding not because their models were wrong but because the clinical layer the team is managing operates below the threshold of family observation. The bilingual nurse who can add that clinical layer in Spanish — in the idiom, directness, and analogical vocabulary families use at home, in the time available in a busy pediatric rheumatology clinic — is bridging a gap that no English-only explanation and no translated handout can close.
For related reading on communication challenges in pediatric specialty clinics where long-term therapy protects against invisible complications, see Spanish for pediatric inflammatory bowel disease clinic nurses (biologic escalation after steroid-induced remission, asymptomatic dysplasia surveillance in UC, CRP versus calprotectin as mucosal markers) and Spanish for pediatric sickle cell disease clinic nurses (the well-appearing child with functional asplenia who needs immediate ED evaluation for fever, TCD screening for asymptomatic stroke vasculopathy). For pediatric clinic nursing in immunologically complex chronic conditions with occult complications, see Spanish for systemic lupus erythematosus clinic nurses and Spanish for pediatric cystic fibrosis clinic nurses. The 50 Spanish ED phrases PDF covers acute presentations including the fever triage and pain localization encounters that precede and sometimes follow pediatric JIA diagnosis conversations. Our full free practice library is available without login. For more long-form clinical-Spanish posts, visit the ClinicaLingo blog.